Rendgenska strukturna analiza i citotoksična aktivnost pikolinato rutenijum(II)-arenskog kompleksa

A ruthenium(II)-arene complex with picolinic acid, [(eta(6)-p-cymene)RuCl(pico)]center dot H(2)O, was prepared by the reaction of [(eta(6)-p-cymene)RuCl(2)](2) with picolinic acid in a 1:2 molar ratio in 2-propanol. The compound was characterized by elemental analysis, and IR and NMR spectroscopy. X-ray diffraction analysis showed that the molecule adopts a "three-leg piano-stool" geometry, which is common for this type of complexes. The cytotoxic activity of the complex was tested in two human cancer cell lines HeLa (cervix) and FemX (melanoma) by MTT assay. The IC(50) values were at 82.0 and 36.2 mu mol dm(-3) for HeLa and FemX cells, respectively.Rutenijum(II)-arenski kompleks sa pikolinskom kiselinom [(η6-p-cimen)RuCl(pikolinato)]·H2O sintetisan je u reakciji [(η6-p-cimen)RuCl2]2 kompleksa sa pikolinskom kiselinom u molskom odnosu 1:2 u izopropanolu. Jedinjenje je okarakterisano elementalnom analizom, IC i NMR spektroskopijom. Analiza difrakcijom X-zracima pokazala je da molekul ima tzv. 'three-leg piano-stool' geometriju koja je karakteristična za ovaj tip kompleksa. Citotoksična aktivnost kompleksa je određena na dve humane tumorske ćelijske linije, HeLa (grlića materice) i FemX (melanoma), MTT testom. IC50 vrednosti su bile 82,0 i 36,2 µmol dm-3 za HeLa i FemX ćelije, redom

New ruthenium(II)-arene complexes bearing hydrazides and the corresponding (thio)semicarbazones of 3-and 4-acetylpyridine: Synthesis, characterization, crystal structure determination and antiproliferative activity

Metal semicarbazone and thiosemicarbazone complexes have attracted much attention due to their diverse biological activities. Because of the ability of ruthenium(II)-arene species to coordinate to different classes of ligands, they are suitable for fine-tuning chemical and pharmaceutical properties. Ruthenium(II) arene-complexes containing different types of ligands: namely caprylic hydrazide (a hydrazide with a long hydrocarbon chain), isonicotinic acid hydrazide (a hydrazide with an aromatic pyridine ring), thiosemicarbazones and semicarbazones (derived from the reaction of 3- and 4-acetylpyridine with either thiosemicarbazide or caprylic hydrazide), were obtained in the reaction of [(eta(6)-p-cymene)RuCl2](2) with the corresponding ligands in a 1:2 or 1:2.2 molar ratio in methanol, ethanol or isopropanol with mild heating. The complexes were characterized by elemental analysis, mass spectrometry, IR and NMR spectroscopies. The structure of complex 1 was determined by X-ray crystallography. Antiproliferative activity of the investigated complexes, determined for three human cancer cell lines (HeLa, A549 and LS-174) revealed moderate activity without significant influence on the matrix metalloproteinases (MMP-2 and MMP-9) activity

Association between tunneled pleural catheter use and infection in patients immunosuppressed from antineoplastic therapy: a multicenter study

Rationale: Patients with malignant/paramalignant pleural effusions (MPE/PMPEs) may have tunneled pleural catheter (TPC) management withheld due to infection concerns from immunosuppression associated with antineoplastic therapy. Objective: To determine the rate of infections related to TPC use and to determine the relationship to antineoplastic therapy, immune system competency and overall survival (OS)? Methods: We performed an international, multi-institutional study of MPE/PMPE patients undergoing TPC management from 2008-2016. Patients were stratified by whether or not they underwent antineoplastic therapy and/or were immunocompromised or not. Cumulative incidence functions and multivariable competing risk regression analyses were performed to identify independent predictors of TPC-related infection. Kaplan-Meier method and multivariable Cox proportional-hazards modeling were performed to examine for independent effects on OS. Results: A total of 1,408 TPCs were placed in 1,318 patients. Patients had a high frequency of overlap between antineoplastic therapy and an immunocompromised state (75-83%). No difference in the overall (6-7%), deep pleural (3-5%) or superficial (3-4%) TPC-related infection rates between subsets of patients stratified by antineoplastic therapy or immune status was observed. The median time to infection was 41 (interquartile range: 19-87) days following TPC insertion. Multivariable competing risk analyses demonstrated longer TPC duration was associated with a higher risk of TPC-related infection [subdistribution hazard ratio (95% CI): 1.03 (1.00-1.06), p=0.028]. Cox proportional-hazards analysis showed antineoplastic therapy was associated with better OS [hazard ratio (95% CI): 0.84 (0.73-0.97), p=0.015]. Conclusion: The risk of TPC-related infection does not appear to be increased by antineoplastic therapy use or an immunocompromised state. The overall rates of infection are low and comparable to immunocompetent patients with no relevant antineoplastic therapy. These results support TPC palliation for MPE/PMPE regardless of plans for antineoplastic therapy.</p